Umbralisib tosylate - Generic Drug Details

What are the generic sources for umbralisib tosylate and what is the scope of freedom to operate?

Umbralisib tosylate is the generic ingredient in one branded drug marketed by Tg Theraps and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Umbralisib tosylate has sixty-eight patent family members in thirty-one countries.

Summary for umbralisib tosylate

International Patents:	68
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	9
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for umbralisib tosylate
DailyMed Link:	umbralisib tosylate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for umbralisib tosylate

Constraining patent/regulatory exclusivity:

10,414,773

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for umbralisib tosylate

L01EX	Other protein kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for umbralisib tosylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	10,072,013
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	10,981,919
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	9,669,033
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	10,947,244
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	9,150,579		Y	Y
Tg Theraps	UKONIQ	umbralisib tosylate	TABLET;ORAL	213176-001	Feb 5, 2021		DISCN	Yes	No	10,570,142		Y	Y

International Patents for umbralisib tosylate

Country	Patent Number	Title	Estimated Expiration
South Africa	201507539	SELECTIVE PI3K DELTA INHIBITORS
Eurasian Patent Organization	201492176	СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ PI3K ДЕЛЬТА
Hong Kong	1209737	選擇性 δ抑制劑 (SELECTIVE PI3K DELTA INHIBITORS PI3K)
Singapore	11201408821S	SELECTIVE PI3K DELTA INHIBITORS
Philippines	12014502865	SELECTIVE PI3K DELTA INHIBITORS
Japan	6416339
Turkey	201908334

Market Dynamics and Financial Trajectory for Umbralisib Tosylate

Last updated: February 22, 2026

What is the current regulatory and market status of umbralisib tosylate?

Umbralisib is a phosphoinositide 3-kinase delta and u (PI3Kδ/γ) inhibitor developed by TG Therapeutics. As of October 2023, it has been approved in the United States for marginal zone lymphoma (MZL) and follicular lymphoma (FL). Its regulatory status varies internationally, with gaps in approvals owing to clinical trial outcomes and strategic considerations. The drug aims to address hematologic malignancies with limited treatment options.

How has clinical development influenced its market prospects?

Clinical trials have played a key role. Phase 3 data demonstrated efficacy in MZL and FL, with overall response rates (ORR) around 55-65%. Adverse events linked to PI3K inhibitors, such as hepatotoxicity and colitis, impacted investor confidence. Trial discontinuations or delays in other indications limit near-term revenue potential. Regulatory approval depends on ongoing trial results in additional indications, especially chronic lymphocytic leukemia (CLL) and other lymphomas.

What are the key drivers impacting its market penetration?

1. Unmet clinical needs: Limited options exist for relapsed/refractory marginal zone and follicular lymphoma. Umbralisib's approval provides an alternative to existing therapies like idelalisib and duvelisib.

2. Competitive landscape: Idelalisib (Gilead), duvelisib (Infinity Pharmaceuticals), and newer agents such as Zandelisib have competing mechanisms and market positions. Umbralisib's differentiated safety profile could influence uptake.

3. Pricing and reimbursement: Estimated patient cost ranges from $10,000 to $13,000 monthly in the US. Reimbursement policies partly hinge on clinical benefit sustainability and adverse event management.

4. Strategic partnerships: TG Therapeutics expanded collaboration with larger pharma companies and academic groups, aiming to broaden indication pipeline and distribution channels.

What is its financial trajectory forecast based on current data?

Revenue projections for umbralisib remain conservative, given regulatory approvals are limited to certain lymphoma subtypes, and competitors maintain dominance.

Year	Estimated US Sales	Assumptions	Notes
2023	$150 million	Post-approval uptake in MZL and FL	Slower initial adoption due to safety concerns
2024	$250 million	Increased market share	Expansion into additional lymphomas pending trial results
2025	$400 million	Broader indication approvals	Potential approval in CLL or other indications
2026	$550 million	Uptake stabilization	International markets opening

Global market expansion remains uncertain, impacted by regulatory hurdles in Europe and Asia.

How do safety profiles influence financial outcomes?

PI3K inhibitors generally face toxicity management issues. Umbralisib's reduced hepatotoxicity and gastrointestinal event rates give it a potential advantage over competitors. Market acceptance depends on clinicians' confidence in managing side effects, affecting prescription volumes and pricing power.

Are there any upcoming regulatory or clinical milestones that could change the forecast?

• Q1 2024: Submission for additional indications, likely in CLL.
• Q2 2024: Mid-year interim analysis of ongoing Phase 3 trials.
• Late 2024: Expected EMA submission, subject to Q1 outcomes.
• 2025: Potential new approvals based on trial efficacy, shifting revenue estimates upward.

What are the risks to the financial trajectory?

• Trial failures: Additional Phase 3 trial failures could halt expansion plans.
• Competitive innovations: Newer PI3K inhibitors with improved safety profiles could erode market share.
• Regulatory delays: Slower approval processes impact revenue timelines.
• Pricing pressures: Reimbursement policies tightening could limit profit margins.

Key Takeaways

• Umbralisib's market success hinges on regulatory approvals, clinical trial outcomes, and safety profile advantages.
• Revenue projections expect growth driven by approval expansion, but face uncertainties from clinical and regulatory risks.
• Competitive landscape remains intense, with established drugs and emerging agents influencing market share.
• Global commercialization depends on regulatory strategies, market access negotiations, and clinical results.

FAQs

1. What indications has umbralisib received approval for?
   Approved in the US for marginal zone lymphoma and follicular lymphoma.

2. What are the main competitors to umbralisib?
   Idelalisib, duvelisib, and emerging agents like Zandelisib.

3. How does the safety profile impact its market?
   Reduced hepatotoxicity and gastrointestinal adverse events may improve clinician confidence and market uptake.

4. What are the key regulatory milestones expected in 2024?
   Submission for additional indications, interim trial analyses, and potential EMA submission.

5. What are the main risks facing its market and financial growth?
   Clinical trial failures, competitive innovations, regulatory delays, and reimbursement challenges.

---

References

1. [1] U.S. Food and Drug Administration. (2023). FDA Approvals and Labeling. FDA.gov.
2. [2] TG Therapeutics. (2023). Annual Financial Reports. TGTherapeutics.com.
3. [3] ClinicalTrials.gov. (2023). Phase 3 trial data and ongoing studies for umbralisib.
4. [4] Market research reports. (2023). Hematologic malignancies drug market.
5. [5] EvaluatePharma. (2023). Pharmaceutical market forecasts.